{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:16:58Z","timestamp":1767831418743,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DFG","award":["HE 5240\/5-2"],"award-info":[{"award-number":["HE 5240\/5-2"]}]},{"name":"DFG","award":["HE 5240\/6-1"],"award-info":[{"award-number":["HE 5240\/6-1"]}]},{"name":"DFG","award":["HE 5240\/6-2"],"award-info":[{"award-number":["HE 5240\/6-2"]}]},{"name":"European Union's Horizon 2020 research and innovation program","award":["638035"],"award-info":[{"award-number":["638035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00277-020-04181-5","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T20:02:47Z","timestamp":1595534567000},"page":"595-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-6316","authenticated-orcid":false,"given":"Rabia","family":"Shahswar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razif","family":"Gabdoulline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Markel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Gohring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Krauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"issue":"5","key":"4181_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","volume":"61","author":"PD Bhola","year":"2016","unstructured":"Bhola PD, Letai A (2016) Mitochondria-judges and executioners of cell death sentences. Mol Cell 61(5):695\u2013704. https:\/\/doi.org\/10.1016\/j.molcel.2016.02.019","journal-title":"Mol Cell"},{"issue":"10","key":"4181_CR2","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A (2016) Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukaemia. Cancer Discov 6(10):1106\u20131117.4. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313","journal-title":"Cancer Discov"},{"key":"4181_CR3","doi-asserted-by":"publisher","unstructured":"Wei AH et al (2020) Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood. https:\/\/doi.org\/10.1182\/blood.2020004856","DOI":"10.1182\/blood.2020004856"},{"issue":"1","key":"4181_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD et al (2019) Venetoclax combined with Decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"issue":"20","key":"4181_CR5","doi-asserted-by":"publisher","first-page":"36079","DOI":"10.1016\/j.annonc.2020.02.018","volume":"S0923-7534","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C (2020) Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol S0923-7534(20):36079\u201336078. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.018","journal-title":"Ann Oncol"},{"issue":"4","key":"4181_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF (2016) Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1513257","journal-title":"N Engl J Med"},{"issue":"20","key":"4181_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"4181_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"M Cairo","year":"2004","unstructured":"Cairo M, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3\u201311. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05094.x","journal-title":"Br J Haematol"},{"issue":"4","key":"4181_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"15","key":"4181_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ (2019) Venetoclax combined with low-dose Cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37(15):1277\u20131284. https:\/\/doi.org\/10.1200\/JCO.18.01600","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04181-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T23:22:27Z","timestamp":1626996147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04181-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["4181"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04181-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MH reports honoraria from Novartis, Pfizer, and PriME Oncology, a consulting or advisory role for Abbvie, Bayer Pharma AG, Daiichi Sankyo, Novartis, and Pfizer, and research funding to the institution from Abbvie, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Karyopharm, Novartis, Pfizer, and Roche. All other authors declare no conflicts of interest. All authors read and agreed to the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}